Everly Health
Runs at-home lab testing and telehealth via a CLIA-certified lab and FDA-cleared kits.
On the record
Checkpoint: Next capital event: a fresh priced round, a down round, or a sale to a lab incumbent
The call
Everly Health holds regulated infrastructure that's hard to copy but has shrunk headcount for years without new funding, leaving it more likely to be bought than to grow on its own.
Everly Health sends lab kits to your home and connects you with doctors by video for results. The company has real advantages: it owns its lab licenses, can operate in all 50 states, and has contracts with health insurance plans. These are hard to build from scratch, but Labcorp and Quest already own bigger lab networks and are moving into the same at-home testing space, so they could copy Everly without much trouble. Meanwhile, cheaper AI chatbots are taking away customers who just want a quick health question answered. The company has cut its workforce roughly in half since 2023, hasn't raised money in over five years, and revenue is flat. The one thing that would change the picture is a fresh investment at a real valuation, which would signal the company still has a shot at independent survival. Otherwise, a sale to Labcorp or Quest looks more likely than a comeback.
Why
01
AI pressure: Verily Health's generative-AI symptom navigator. AI triage tools handle result interpretation and symptom checking, pulling value away from Everly's consumer-facing layer, not its lab core. Could AI do the core job? Unlikely.
02
Bigger players: Labcorp and Quest Diagnostics. Both run bigger national lab networks and are pushing into consumer at-home testing and health-plan HEDIS work that overlaps Everly's business. Could a giant copy it? Yes, easily.
03
What protects it. A working CLIA lab, FDA licensing, 50-state telehealth reach, and multi-year health-plan contracts that are slow to replicate or switch away from.
What would change this call
Everly Health announces a new priced funding round within 12 months. Would show whether investors still value it at or above 2020's ~$1.3B mark.
Labcorp or Quest launches a branded at-home or HEDIS-gap testing product. Would confirm incumbents are competing directly rather than just being structurally able to.
Everly Health headcount or revenue figures reported again by press or trackers. Would show whether the 55% headcount contraction has stabilized or continued.
Labcorp or Quest launches a branded at-home or HEDIS-gap testing product. Would confirm incumbents are competing directly rather than just being structurally able to.
Everly Health headcount or revenue figures reported again by press or trackers. Would show whether the 55% headcount contraction has stabilized or continued.
Key numbers
- $175M Series D in Dec 2020 at ~$1.3B valuation
- $75M added from HealthQuest Capital, Jan 2021
- ~700 employees before a 16% layoff, Jan 2023
Named risks
- No priced funding round since 2021 despite five-plus years and workforce contraction.
- Headcount fell from ~700 in January 2023 to an estimated ~319 by late 2025.
- AI-native symptom checkers like Verily Me's Violet eroding the DTC triage and interpretation layer.
- Labcorp and Quest Diagnostics not structurally barred from expanding into at-home and HEDIS-gap consumer segments.
- Prior class action over false or misleading test-product claims settled but signals ongoing regulatory/marketing exposure.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Labcorp and Quest Diagnostics | losing to | Incumbents already own superior phlebotomy-based lab scale and are not structurally barred from consumer/HEDIS segments, as of 2026-03-20 |
| Verily Health (Alphabet spinout) | losing to | Shipped AI symptom navigator Violet in Verily Me app, generally available Feb-March 2026, eroding triage layer |
| LetsGetChecked | contesting | Closest direct peer with own labs and overlapping test menu for enterprise and subscription customers, cited n.d. via testing.com |
| myLAB Box and Nurx | contesting | Named among top at-home STI test providers alongside Everlywell in 2025-10-19 media roundup |
| Quest Health (Quest Diagnostics consumer arm) | gaining on | Positioned as lab-visit alternative to Everlywell's mail-in model per 2026-06-01 comparison |
Questions people ask
- Is Everly Health profitable in 2026?
- No public profitability figures exist since Everly Health is privately held. A third-party aggregator estimated 2025 revenue around $100M, but this is a source estimate, not company-confirmed, and no profit data has been disclosed as of July 2026.
- Has Everly Health raised new funding recently?
- No priced round has been publicly reported since Everly Health raised $75M from HealthQuest Capital in January 2021, following its $175M Series D in December 2020 that set a roughly $1.3B valuation. As of July 2026, secondary-market trackers still cite that stale figure.
- Is Everly Health laying off employees?
- Everly Health announced a 16% workforce reduction around January 2023 when headcount was just over 700, followed by a second layoff round in February 2023 per employee reviews. A late-2025 estimate put headcount near 319, suggesting continued shrinkage.
- Who are Everly Health's biggest competitors?
- Everly Health competes with direct-to-consumer peer LetsGetChecked, at-home testing rivals myLAB Box and Nurx, and lab-visit alternatives Personalabs and Quest Health. Larger incumbents Labcorp and Quest Diagnostics have far greater phlebotomy and lab-network scale.
- Could AI replace Everly Health's business?
- AI can erode Everly Health's consumer-facing symptom triage and result-interpretation layer, as seen with Alphabet spinout Verily Health's AI symptom navigator Violet made generally available February-March 2026. But Everly Health's CLIA lab, FDA licensing, and clinical liability infrastructure cannot be replicated by software alone.
- Is Everly Health a safe company to join right now?
- Headcount has fallen from roughly 700 employees in January 2023 to an estimated 319 by late 2025, alongside no new funding round since 2021. This pattern of contraction without fresh capital signals elevated instability risk for prospective employees as of mid 2026.
Timeline
- 2026-02Alphabet spinout Verily Health made AI symptom navigator Violet generally available in Verily Me app
- 2025-11-26Aggregator Latka estimated Everly Health at ~$100M revenue and ~319 employees
- 2025-04-29Reedy v. Everlywell class action settlement received final court approval, $1M fund
- 2024-09Reedy v. Everlywell class action amended to add Natalist as defendant
- 2024-04Class action Reedy et al. v. Everlywell filed in N.D. Illinois
- 2023-02Second round of layoffs at Everly Health per employee reviews
- 2023-01Everly Health announced 16% workforce reduction, headcount just over 700
- 2022-05Everlywell launched first iOS app with Spotwell computer-vision sample-validation tool
- 2021-10Everly Health acquired women's health brand Natalist
- 2021-01Everly Health raised additional $75M from HealthQuest Capital
- 2020-12Everlywell raised oversubscribed $175M Series D, reaching ~$1.3B unicorn valuation
- 2015-06Everlywell founded in Austin by Julia Cheek and Bobby Matson
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- What is Brief History of Everly Health Company? (2026-03-15)
- Spectrum Equity-Backed PWNHealth is Acquired by Everlywell to Form Everly Health
- Everly Health IPO Timeline and Financing Details (2023-11-14)
- Sell or Invest in Everly Health Stock Pre-IPO (2026-07-07)
- $100M Est. ARR, $1.3B Valuation (2025-11-26)
- How Does Everly Health Company Work? (2026-03-16)
- Tech layoff rumors abound (are Dell & Everly Health up next?) (2023-01-31)
- Everly Health Q&A (2023-09-30)
- Innovative at-home Health Testing
- Everly Health Accelerates Position as Leading Digital Health Company with Acquisition of Women's Health Brand (2021-10-21)
- Everlywell Expands its Nutritional Health Suite... (2022-05-03)
- reedy-et-al-v-everlywell-inc-et-al-settlement-agreement